Chlamydia Outer Protein (Cop) B from Chlamydia pneumoniae possesses characteristic features of a type III secretion (T3S) translocator protein
© Bulir et al. 2015
Received: 24 February 2015
Accepted: 3 August 2015
Published: 14 August 2015
Chlamydia spp. are believed to use a conserved virulence factor called type III secretion (T3S) to facilitate the delivery of effector proteins from the bacterial pathogen to the host cell. Important early effector proteins of the type III secretion system (T3SS) are a class of proteins called the translocators. The translocator proteins insert into the host cell membrane to form a pore, allowing the injectisome to dock onto the host cell to facilitate translocation of effectors. CopB is a predicted hydrophobic translocator protein within the chlamydial T3SS.
In this study, we identified a novel interaction between the hydrophobic translocator, CopB, and the putative filament protein, CdsF. Furthermore, we identified a conserved PxLxxP motif in CopB (amino acid residues 166–171), which is required for interaction with its cognate chaperone, LcrH_1. Using a synthetic peptide derived from the chaperone binding motif of CopB, we were able to block the LcrH_1 interaction with either CopB or CopD; this CopB peptide was capable of inhibiting C. pneumoniae infection of HeLa cells at micromolar concentrations. An antibody raised against the N-terminus of CopB was able to inhibit C. pneumoniae infection of HeLa cells.
The inhibition of the LcrH_1:CopB interaction with a cognate peptide and subsequent inhibition of host cell infection provides strong evidence that T3S is an essential virulence factor for chlamydial infection and pathogenesis. Together, these results support that CopB plays the role of a hydrophobic translocator.
Chlamydia infections represent a significant disease burden worldwide. C. trachomatis infection can lead to pelvic inflammatory disease (PID), salpingitis, and infertility in women and epididymitis and infertility among men . Furthermore, Chlamydia pneumoniae is a respiratory pathogen causing approximately 10 % of community acquired pneumonia . Additionally, C. pneumoniae infections have been associated with asthma exacerbations, cardiovascular disease, Multiple Sclerosis, and Alzheimer’s [3–7]. Combined, C. pneumoniae and C. trachomatis represent a significant disease burden. An essential component of Chlamydia’s survival is creating an environmental niche that exhibits the necessary requirements for replication and survival. Type III secretion (T3S) is a complex mechanism utilized by important Gram-negative bacterial pathogens. Salmonella, Shigella, Yersinia, Pseudomonas, and Chlamydia all contain the highly conserved type III secretion system (T3SS) of approximately 20–30 proteins [8–11]. To manipulate their host environment, these bacteria secrete toxic effector proteins directly into their target cell. Functionally, the whole apparatus can be referred to as an injectisome; however, it consists of smaller functional components, which include the cytoplasmic C-ring, the inner and outer membrane rings, the needle complex, and needle-tip complex [8–10, 12]. Each of these components display numerous essential protein-protein interactions. Despite the identification and characterization of many putative T3S proteins, it remains unclear whether Chlamydia truly has a functional T3SS, and whether it plays a role in replication and survival given the absence of a robust genetic manipulation system for gene knockouts .
Chlamydia spp. undergo a unique biphasic life-cycle starting with an infectious, non-metabolically active elementary body (EB) [14–16]. Upon attachment of the EB to the host cell, there is a conformational change within the host membrane that allows for invasion of the EB into a membrane-derived vacuole termed an inclusion . Once inside the inclusion, an as of yet unknown signal triggers differentiation of the EB into a metabolically-active, non-infectious reticulate body (RB) that divides through binary fission until late in the infection cycle . The infectious EB will then leave either through a packaged release mechanism, called extrusion, or through cell lysis, to repeat the infection cycle [17–19]. Throughout this process the T3SS is belived to play an essential role in pathogenicity .
The translocator proteins of the T3S system are believed to be critical to the survival of Chlamydia, by forming a pore in the host cell membrane to allow for translocation of effector proteins from the bacterial cytosol to the host cell cytoplasm [8–10]. Analysis of the chlamydial genome suggests that there may be two sets of translocator proteins, CopB and B2 and CopD and D2, both of which are located in the same operon as a predicted class II chaperone . To date, there has been limited characterization of the translocator proteins from Chlamydia spp. Early work on the translocator proteins in Chlamydia indicated that both CopB and CopB2 can be secreted from Yersinia spp. in a T3S-dependent manner and that Scc2 co-precipitated with CopB from a C. trachomatis infected monolayer . More recently, localization experiments have shown that CopB and CopB2, when ectopically expressed in HeLa cells, associate with the cytoplasmic and inclusion membrane, respectively . Our laboratory has previously characterized the minor hydrophobic translocator (CopD) from Chlamydia pneumoniae. We have shown that it associates with T3S components and contains an essential PxLxxP motif for interaction with its class II chaperone, LcrH_1 . Although many hypotheses can be made regarding the possible function of the translocator proteins based on orthologous T3SS translocator proteins, there is limited information on the biochemical characterization of chlamydial translocator proteins owing to the inherent difficulties of working Chlamydia spp.
In this report, we characterize the putative T3SS translocator protein CopB of C. pneumonia, explore interactions between CopB and other T3SS proteins, and characterize the chaperone binding domain of CopB. In addition, we generated a novel peptide mimetic that blocks the interaction between the translocators, CopB and CopD, and their chaperone, LcrH_1, and showed that the peptide mimetic prevents infection. We also identify a CopB epitope which is immunogenic and elicits neutralizing antibodies that block C. pneumoniae infection supporting an essential role for CopB in the infection of host cells.
T3SS genes were cloned via PCR using genomic DNA from C. pneumoniae CWL029 . Fragments of CopB, excluding the transmembrane domains, were cloned due to toxicity of full length CopB in E. coli. Using the Gateway cloning system (Invitrogen) the following genes were cloned into the pDONR201 vector with attB-containing primers (note: subscript denotes amino acid number): lcrH_1, copN, copD 1–157 , cpn0803, copB 1–180 , copB 1–200 , copB 1–255 , copB 275–382 , copB 407–493 , P166A copB 1–200 , L168A copB 1–200 , and P168A copB 1–200 . Each of the pDONR201 vectors were then used in an LR reaction to transfer the gene into expression vectors, pDEST17 (N-Terminal 6xHis-tag), pDEST15 (N-Terminal GST-tag) and pDEST-HisMBP (N-Terminal 6xHis-Maltose Binding Protein-tag). Prior to protein expression, all constructs were verified by Sanger sequencing at the MOBIX laboratory (McMaster University).
Protein expression and purification
All constructs were transformed into E. coli BL21 and recombinant protein was expressed following induction with Isopropyl β-D-thiogalactopyranoside (IPTG). Protein expression and purification were performed as described by Bulir et al. (2014), with the following modifications . Briefly, 6 L of LB containing 100 μg/mL ampicillin was inoculated with 1:100 dilution of an overnight culture and split equally into 6x 2 L flasks. The cultures were then grown at 37 °C with shaking at 250 RPM until an optical density of 0.500 at 600 nm was reached. Cultures were induced with 0.2 mM IPTG and were left incubating at room temperature, shaking at 250 RPM for 3 h.
Glutathione-S-transferase (GST) pull-down assay
Glutathione-S-transferase pull-down assays were performed as described by Bulir et al. (2014) . Briefly, GST-tagged proteins were bound to 1 mL GST beads for one hour at 4 °C on a mixing platform. GST beads were centrifuged at 3000 x g for 5 min to remove the supernatant and then blocked with blocking solution (5 % BSA in PBS + 0.1 % TWEEN-20) overnight at 4 °C. Blocked beads (50–100 μL) were mixed with E. coli lysates containing overexpressed His-tagged protein for one hour. For experiments involving the blockade of interaction between GST- and His-tagged constructs, the chemically synthesized peptide was incubated with the bait construct for 1 h at 4 °C prior to the addition of the overexpressed His-tagged E. coli lysate. The beads were then centrifuged at 16,000 × g for 10 s, the supernatant was removed, and the pellet was washed with high salt wash buffer (500 mM KCl, 20 mM Tris–HCl pH 7.0, 0.1 % Triton X-100). The washing procedure was repeated seven times to ensure complete removal of adventitiously bound protein. For GST pull-downs involving synthetically produced peptide, the peptides were used at a concentration of 500 µM. The glutathione-agarose beads were then resuspended in 75 μL of SDS-PAGE loading dye. The samples were analysed by SDS-PAGE and Western blot analysis using a mouse anti-His antibody (GenScript, New Jersey).
Orthologous proteins to CopB were identified using BLASTP (Basic Local Alignment Search Tool Protein) and PSI-BLAST, excluding Chlamydiaceae family from the search. CopB was analyzed using the TMpred software tool to predict transmembrane domains, using a minimum transmembrane window of 17 and maximum of 33. Coiled-coil prediction software, COILS, was used to predict the presence of coiled-coil domains within CopB, using the MTIDK scoring matrices, and weighting for positions a & d.
Antibody and peptide inhibition of C. pneumoniae infection in HeLa cells
Infection was performed as previously described by Johnson et al. . At approximately 72 h post infection, chlamydial inclusions were stained with the Pathfinder Chlamydia detection reagent (BioRad) and visualized with multiple, random fields of view. Percent reduction of infection was calculated compared to a control infection, and statistical significance was calculated using a Student’s t-test. A polyclonal antibody raised against a 15 amino acid peptide (SGKDKTSSTTKTETC) from CopB was obtained from GenScript (New Jersey). C. pneumoniae was pre-incubated for 2 h at 37 °C with dilutions of affinity purified CopB antibody, control antibody (anti-GST), or pre-immunization sera. Additionally, chlamydial infection inhibition was performed using a synthetic peptide (500 uM), vehicle alone (PBS), or control peptide (anti-RSV peptide). Briefly, 5×105 IFUs were incubated with the peptide or vehicle alone (PBS) for 2 h at 37 °C prior to performing a standard infection and inclusions were visualized as previously described.
Bioinformatic analysis of Chlamydia outer protein (Cop) B
CopB interacts with the putative needle filament protein, CdsF
LcrH_1 interacts within the N-terminus of CopB
A CopB peptide mimetic blocks the LcrH_1 and CopB interaction
Anti-CopB antibody inhibits C. pneumoniae
Despite our increasing understanding of the T3SS in Chlamydia spp., there is limited or no evidence for a direct role for the translocator proteins during infection. Our laboratory has previously characterized the putative minor hydrophobic translocator, CopD, showing that it plays an essential role during chlamydial infection . In this report, we provide an initial characterization of the major hydrophobic translocator, CopB. The interaction of CopB with the filament protein CdsF suggests that it plays an essential role in T3S. As seen with other translocator proteins, the putative chaperone located immediately upstream of CopB interacted with the first N-terminal 200 amino acids of CopB. Using an alanine walkthrough of the conserved PxLxxP motif, we show that amino acids P166, L168, and P171, in addition to amino acids 180–200, are required for the interaction between CopB and its’ cognate chaperone LcrH_1. We demonstrated that a cognate CopB peptide encompassing the chaperone binding motif can block the interaction between LcrH_1 and both CopB and CopD, suggesting that the CBD is a critical binding domain. Furthermore, we show that this peptide when pre-incubated with C. pneumoniae, blocked infection. Together, these results strongly suggest that the PxLxxP motif is required for the translocator-chaperone interaction, and for infection. We also show that a polyclonal antibody raised against an N-terminal epitope within CopB significantly reduced infection. Collectively, these results are consistent with CopB’s role as a translocator within the Chlamydia T3SS.
Initial bioinformatic studies were performed to gain insight into the role of CopB in C. pneumoniae [21–23]. Chellas-Géry et al. identified potential hydrophobic and coiled-coil domains within CopB from C. trachomatis . Given the moderate level of sequence identity between C. trachomatis and C. pneumoniae CopB (approximately 52 % amino acid identity), a thorough bioinformatics analysis of CopB was performed. BLASTP analysis of CopB yielded one significant result from Bacteroides fragilis, typically a commensal bacterium found in the gastrointestinal tract, but no matches were found for other T3S systems, suggesting that the C. pneumoniae T3SS may be quite unique among orthologous systems, which is in keeping with Chlamydiae containing an ancient T3SS. Although no orthologous sequences of the chlamydial translocator proteins were identified in the archetypal secretion systems using our bioinformatics approach, the proteins are predicted to have similar structure and function. Since CopB is likely anchored within the host-cell cytoplasm to facilitate translocation of effector proteins, we utilized TMpred online software to identify potential transmembrane regions. Our analysis identified two potential transmembrane domains spanning amino acids 256–274 and 383–406, respectively. This is consistent with other translocator proteins possessing two transmembrane domains to anchor themselves within the host cell membrane [27, 28]. Using the COILS online prediction software, we identified three potential coiled-coil domains, which may be important for mediating protein-protein or protein-membrane interactions. The N-terminus of CopB contains a conserved PxLxxP motif, followed by a sequence of hydrophobic amino acids, which is seen in other translocator proteins from C. pneumonia, and has been shown to be important for mediating the essential translcoator:chaperone interaction in other bacterial systems (Shigella, Yersinia, Salmonella) .
Due to the difficulty in genetically manipulating Chlamydia and the inherent challenges of establishing structure-function relationships for T3S proteins of obligate intracellular pathogens dependent on T3S for infection, it is difficult to ascertain the role of chlamydial T3SS proteins. We therefore explored the possible interaction between CopB and other proteins within the chlamydial T3SS. The needle filament protein, CdsF in Chlamydia, is believed to polymerize forming needle structure for the translocation of effector proteins. The translocator proteins are believed to be docked on the tip of the injectisome to form the needle-tip complex, prior to host cell contact. Two domains of CopB, amino acids 1–255 and 275–382, interacted with CdsF using a GST-pulldown assay. CopN, the putative plug protein, is believed to be localized to the base of the needle apparatus and prevents premature secretion of effector proteins. No apparent interaction between CopN and CopB was observed using a GST-pulldown assay. Although an interaction was observed between CopD and CopN, the lack of interaction between CopB and CopN suggests that CopB may be secreted through the apparatus and docked on the end of the needle complex before CopN plugs the needle apparatus. Considering the fact that recent work has suggested that Cpn0803 may be a chaperone protein given its biophysical properties and putative interactions, it is not surprising that CopB failed to interact with Cpn0803 [29, 30]. The interaction between CopB and the needle filament protein, CdsF, in this report is a novel observation not previously reported in the literature. It has been reported that the translocators are recruited to the tip of the needle complex either upon detecting host cell contact or under secretion conditions. Once the translocators are inserted into the host cell membrane, the filament protein must anchor to the host cell via the translocator proteins, which are now imbedded in the host membrane. This result is consistent with the role of the hydrophobic translocator proteins in other T3SS since the needle protein must interact with the translocator proteins on the host cell to facilitate translocation of effector proteins [31, 32].
Comparison of putative chaperone binding domains between Chlamydiaceae family members and other T3SS containing Gram-negative bacteria
CopB (C. pneumoniae)
CT578 (C. trachomatis serovar D)
SseC like family protein (C. psittaci)
TC_0867 (C. muridarum)
CPE1_0913 (C. pecorum)
CAB923 (C. abortus S26/3)
PopB (Y. enterocolitica)
IpaB (S. dyseteriae)
The co-crystal structure of class II chaperones (LcrH_1 orthologs) with the translocator PxLxxP domain confirms the interaction between the two proteins . Based on this interaction we hypothesized that a cognate peptide of CopB containing the PxLxxP peptide sequence could disrupt the translocator-chaperone interaction. We therefore tested a peptide containing the 10 amino acids encompassing the PxLxxP domain plus a cell penetrating peptide sequence to test this hypothesis. Since the PxLxxP motif is conserved between CopB and CopD, we pre-incubated LcrH_1 with the cognate peptide then added either CopB or CopD fragments to the GST pull down and showed that the peptide blocked the interaction between LcrH_1, and CopB and CopD. Since the cell penetrating peptide sequence allows proteins to enter cells, we hypothesized that this cognate peptide would block chlamydial infection and intracellular replication [34, 35]. After pre-treating C. pneumoniae with this peptide, we observed a significant reduction of 90 %, compared to control infection, with vehicle alone. Since it is currently not possible to create genetic knockouts in Chlamydia, peptide mimetics could be used to create functional knockouts to study the resultant phenotype. The peptides ability to significantly reduce infection reinforces the importance of the chaperone binding motif for the chaperone-translocator interaction and may represent a novel target for therapeutic intervention using peptide mimetics.
Antibodies to the translocator proteins in orthologous secretion systems have been shown to inhibit infection, suggesting that the translocator proteins play an essential role during infection [36–40]. Using antibodies raised to an N-terminal epitope of CopB, we demonstrated that anti-CopB antibodies inhibited C. pneumoniae infection by 98 %. Inhibition of infection by anti-CopB antibodies indicates that CopB is surface exposed at some time during infection and play an essential role in infection. Given the fact that CopB is surface exposed during the initial phase of chlamydial infection, the translocator proteins may represent a novel class of antigens for use in vaccination strategies to prevent chlamydial infections.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Hook E, Handsfield HH. Gonococcal infections in the adult. New York: McGraw-Hill; 2008.Google Scholar
- Heiskanen-Kosma T, Korppi M, Laurila A, Jokinen C, Kleemola M, Saikku P. Chlamydia pneumoniae is an important cause of community-acquired pneumonia in school-aged children: serological results of a prospective, population-based study. Scand J Infect Dis. 1999;31(3):255–9.View ArticlePubMedGoogle Scholar
- Hahn DL, Azenabor AA, Beatty WL, Byrne GI. Chlamydia pneumoniae as a respiratory pathogen. Front Biosci. 2002;7:e66–76.View ArticlePubMedGoogle Scholar
- Sutherland ER, Martin RJ. Asthma and atypical bacterial infection. Chest. 2007;132(6):1962–6.View ArticlePubMedGoogle Scholar
- Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, Grayston JT. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis. 1997;176(1):292–5.View ArticlePubMedGoogle Scholar
- Contini C, Seraceni S, Cultrera R, Castellazzi M, Granieri E, Fainardi E. Molecular detection of Parachlamydia-like organisms in cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2008;14(4):564–6.View ArticlePubMedGoogle Scholar
- Gerard HC, Dreses-Werringloer U, Wildt KS, Deka S, Oszust C, Balin BJ, et al. Chlamydophila (Chlamydia) pneumoniae in the Alzheimer’s brain. FEMS Immunol Med Microbiol. 2006;48(3):355–66.View ArticlePubMedGoogle Scholar
- Cornelis GR. The type III secretion injectisome, a complex nanomachine for intracellular ‘toxin’ delivery. Biol Chem. 2010;391(7):745–51.View ArticlePubMedGoogle Scholar
- Cornelis GR. The type III secretion injectisome. Nat Rev Microbiol. 2006;4(11):811–25.View ArticlePubMedGoogle Scholar
- Betts-Hampikian HJ, Fields KA. The chlamydial type III secretion mechanism: revealing cracks in a tough nut. Front Microbiol. 2010;1:114.PubMed CentralView ArticlePubMedGoogle Scholar
- Beeckman DS, Vanrompay DC. Bacterial secretion systems with an emphasis on the chlamydial type III secretion system. Curr Issues Mol Biol. 2010;12(1):17–41.PubMedGoogle Scholar
- Mueller KE, Plano GV, Fields KA. New frontiers in type III secretion biology: the chlamydia perspective. Infect Immun. 2014;82(1):2–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Hsia RC, Pannekoek Y, Ingerowski E, Bavoil PM. Type III secretion genes identify a putative virulence locus of Chlamydia. Mol Microbiol. 1997;25(2):351–9.View ArticlePubMedGoogle Scholar
- Johnson DL, Mahony JB. Chlamydophila pneumoniae PknD exhibits dual amino acid specificity and phosphorylates Cpn0712, a putative type III secretion YscD homolog. J Bacteriol. 2007;189(21):7549–55.PubMed CentralView ArticlePubMedGoogle Scholar
- Johnson DL, Stone CB, Bulir DC, Coombes BK, Mahony JB. A novel inhibitor of Chlamydophila pneumoniae protein kinase D (PknD) inhibits phosphorylation of CdsD and suppresses bacterial replication. BMC Microbiol. 2009;9:218.PubMed CentralView ArticlePubMedGoogle Scholar
- Dautry-Varsat A, Subtil A, Hackstadt T. Recent insights into the mechanisms of Chlamydia entry. Cell Microbiol. 2005;7(12):1714–22.PubMedGoogle Scholar
- Hybiske K, Stephens RS. Exit strategies of intracellular pathogens. Nat Rev Microbiol. 2008;6(2):99–110.View ArticlePubMedGoogle Scholar
- Hybiske K, Stephens RS. Mechanisms of host cell exit by the intracellular bacterium Chlamydia. Proc Natl Acad Sci U S A. 2007;104(27):11430–5.PubMed CentralView ArticlePubMedGoogle Scholar
- Hybiske K, Stephens RS. Mechanisms of Chlamydia trachomatis entry into nonphagocytic cells. Infect Immun. 2007;75(8):3925–34.PubMed CentralView ArticlePubMedGoogle Scholar
- Ouellette SP, Abdelrahman YM, Belland RJ, Byrne GI. The Chlamydia pneumoniae type III secretion-related lcrH gene clusters are developmentally expressed operons. J Bacteriol. 2005;187(22):7853–6.PubMed CentralView ArticlePubMedGoogle Scholar
- Fields KA, Fischer ER, Mead DJ, Hackstadt T. Analysis of putative chlamydia trachomatis chaperones Scc2 and Scc3 and their use in the identification of type III secretion substrates. J Bacteriol. 2005;187(18):6466–78.PubMed CentralView ArticlePubMedGoogle Scholar
- Chellas-Gery B, Wolf K, Tisoncik J, Hackstadt T, Fields KA. Biochemical and localization analyses of putative type III secretion translocator proteins CopB and CopB2 of chlamydia trachomatis reveal significant distinctions. Infect Immun. 2011;79(8):3036–45.PubMed CentralView ArticlePubMedGoogle Scholar
- Bulir DC, Waltho DA, Stone CB, Mwawasi KA, Nelson JC, Mahony JB. Chlamydia pneumoniae CopD translocator protein plays a critical role in type III secretion (T3S) and infection. PLoS One. 2014;9(6):e99315.PubMed CentralView ArticlePubMedGoogle Scholar
- Dewoody RS, Merritt PM, Marketon MM. Regulation of the Yersinia type III secretion system: traffic control. Front Cell Infect Microbiol. 2013;3:4.PubMed CentralView ArticlePubMedGoogle Scholar
- Ide T, Laarmann S, Greune L, Schillers H, Oberleithner H, Schmidt MA. Characterization of translocation pores inserted into plasma membranes by type III-secreted Esp proteins of enteropathogenic Escherichia coli. Cell Microbiol. 2001;3(10):669–79.View ArticlePubMedGoogle Scholar
- Olive AJ, Kenjale R, Espina M, Moore DS, Picking WL, Picking WD. Bile salts stimulate recruitment of IpaB to the Shigella flexneri surface, where it colocalizes with IpaD at the tip of the type III secretion needle. Infect Immun. 2007;75(5):2626–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Adam PR, Dickenson NE, Greenwood 2nd JC, Picking WL, Picking WD. Influence of oligomerization state on the structural properties of invasion plasmid antigen B from Shigella flexneri in the presence and absence of phospholipid membranes. Proteins. 2014;82(11):3013–22.View ArticlePubMedGoogle Scholar
- Lunelli M, Lokareddy RK, Zychlinsky A, Kolbe M. IpaB-IpgC interaction defines binding motif for type III secretion translocator. Proc Natl Acad Sci U S A. 2009;106(24):9661–6.PubMed CentralView ArticlePubMedGoogle Scholar
- da Cunha M, Milho C, Almeida F, Pais SV, Borges V, Mauricio R, et al. Identification of type III secretion substrates of Chlamydia trachomatis using Yersinia enterocolitica as a heterologous system. BMC Microbiol. 2014;14:40.PubMed CentralView ArticlePubMedGoogle Scholar
- Pais SV, Milho C, Almeida F, Mota LJ. Identification of novel type III secretion chaperone-substrate complexes of Chlamydia trachomatis. PLoS One. 2013;8(2):e56292.PubMed CentralView ArticlePubMedGoogle Scholar
- Dickenson NE, Arizmendi O, Patil MK, Toth RT, Middaugh CR, Picking WD, et al. N-terminus of IpaB provides a potential anchor to the Shigella type III secretion system tip complex protein IpaD. Biochemistry. 2013;52(49):8790–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Espina M, Olive AJ, Kenjale R, Moore DS, Ausar SF, Kaminski RW, et al. IpaD localizes to the tip of the type III secretion system needle of Shigella flexneri. Infect Immun. 2006;74(8):4391–400.PubMed CentralView ArticlePubMedGoogle Scholar
- Adam PR, Patil MK, Dickenson NE, Choudhari S, Barta M, Geisbrecht BV, et al. Binding affects the tertiary and quaternary structures of the Shigella translocator protein IpaB and its chaperone IpgC. Biochemistry. 2012;51(19):4062–71.PubMed CentralView ArticlePubMedGoogle Scholar
- Choi YS, David AE. Cell penetrating peptides and the mechanisms for intracellular entry. Curr Pharm Biotechnol. 2014;15(3):192–9.View ArticlePubMedGoogle Scholar
- Jones AT, Sayers EJ. Cell entry of cell penetrating peptides: tales of tails wagging dogs. J Control Release. 2012;161(2):582–91.View ArticlePubMedGoogle Scholar
- Chen X, Choudhari SP, Martinez-Becerra FJ, Kim JH, Dickenson NE, Toth RT, et al. Impact of detergent on the biophysical properties and immune response of the IpaDB Fusion protein, a candidate subunit vaccine against Shigella spp. Infect Immun. 2015;83:292.PubMed CentralView ArticlePubMedGoogle Scholar
- Heine SJ, Diaz-McNair J, Andar AU, Drachenberg CB, van de Verg L, Walker R, et al. Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes. J Immunol. 2014;192(4):1630–40.PubMed CentralView ArticlePubMedGoogle Scholar
- Martinez-Becerra FJ, Chen X, Dickenson NE, Choudhari SP, Harrison K, Clements JD, et al. Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine. Infect Immun. 2013;81(12):4470–7.PubMed CentralView ArticlePubMedGoogle Scholar
- Heine SJ, Diaz-McNair J, Martinez-Becerra FJ, Choudhari SP, Clements JD, Picking WL, et al. Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. Vaccine. 2013;31(28):2919–29.PubMed CentralView ArticlePubMedGoogle Scholar
- Martinez-Becerra FJ, Scobey M, Harrison K, Choudhari SP, Quick AM, Joshi SB, et al. Parenteral immunization with IpaB/IpaD protects mice against lethal pulmonary infection by Shigella. Vaccine. 2013;31(24):2667–72.View ArticlePubMedGoogle Scholar